Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2007

Avanir’s Value More Than Doubled on Phase III Results of Diabetic Neuropathic Pain Drug

  • Avanir Pharmaceuticals reported positive results from the Phase III evaluation of its diabetic neuropathic pain drug. The company’s shares soared 165% to open trading at $3.37.

    Zenvia (dextromethorphan hydrobromide/quinidine sulfate (DMQ)) is an NMDA antagonist and sigma-1 agonist. In the trial, two doses of Zenvia, 45/30 mg DMQ and 30/30 mg DMQ, both dosed twice daily, were compared to placebo. Both treatment groups had lower pain ratings than placebo patients. The drug also showed statistically significant improvements in a number of secondary endpoints, including pain relief and pain intensity.

    Zenvia is also in development for the treatment of involuntary emotional expression disorder.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »